News
Bristol Myers, anemia
Bristol Myers' Drug Flunks Blood Cancer-Associated Anemia Trial
Bristol Myers Squibb & Co. (NYSE:BMY) on Friday announced topline results from the Phase 3 INDEPENDENCE trial evaluating Reblozyl (luspatercept-aamt) with concomitant janus kinase inhibitor (JAKi) therapy in adult patients with myelofibrosis-associated anemia receiving red blood cell (RBC) transfusions.
3d
To get a sense of who is truly in control of Bristol-Myers Squibb Company (NYSE:BMY), it is important to understand the ...
23hon MSN
Bristol-Myers Squibb Company (NYSE:BMY) is one of the largest and most well-known American pharmaceutical companies.
This was the stock's second consecutive day of losses.
Zacks Investment Research on MSN3d
Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on ItBristol Myers Squibb (BMY) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to ...
The companies' new effort would bypass traditional middlemen to cut the drug's monthly cost from a list price of around $606 ...
Bristol-Myers Squibb Company (NYSE:BMY) is included among the 14 Best Pharma Dividend Stocks to Buy in 2025. The company has ...
US FDA accepts Bristol Myers Squibb’s sNDA for Sotyktu to treat adults with active psoriatic arthritis: Princeton, New Jersey Tuesday, July 22, 2025, 12:00 Hrs [IST] Bristol Mye ...
Bristol Myers Squibb is undervalued despite challenges. Learn how BMY stock's strong pipeline, cash flow, and growth ...
Bristol Myers and Pfizer will sell Eliquis directly to U.S. patients at a discounted rate with transparent pricing and ...
Bristol Myers Squibb Co. closed 26.69% short of its 52-week high of $63.33, which the company achieved on March 11th.
Bristol Myers Squibb is making progress paying down debt from prior deals and improving financial flexibility so it can make ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results